Joint with: Multispecific Immune Cell Engagers for Cancer Immunotherapy
Next Generation Antibody Therapeutics: From Discovery to Patient
February 19-22, 2023 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
Pamela M. Holland and James A. Wells
In Person
On Demand
February 19-22, 2023 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
Pamela M. Holland and James A. Wells
Available Formats:
In Person
On Demand
Supported by the Directors' Fund
Available Formats: = In Person = On Demand
Booking Function
Fundraising
Merchandise Options
Registration Options
Sunday, February 19, 2023
Arrival and Registration
4:00–8:00 PM
Riverview Lounge
Welcome Mixer
6:00–8:00 PM
Riverview Lounge
Monday, February 20, 2023
Breakfast
7:00–8:00 AM
Alberta/New Brunswick
Welcome and Keynote Address (Joint)
8:00–9:00 AM
Cascade Ballroom
* Pamela M. Holland, InduPro
Session Chair
Session Chair
* Pablo Umaña, Roche Innovation Center Zürich
Session Chair
Session Chair
* James A. Wells, University of California, San Francisco
Session Chair
Session Chair
Tomoyuki Igawa, Chugai Pharmaceutical
Conditional Activation of Antibody Therapeutics in the Tumor Microenvironment
Conditional Activation of Antibody Therapeutics in the Tumor Microenvironment
Conditional Targeting with Multi-Specific Engagers (Joint)
9:00–11:15 AM
Cascade Ballroom
Pamela M. Holland, InduPro
Session Chair
Session Chair
Pablo Umaña, Roche Innovation Center Zürich
Session Chair
Session Chair
Katarina Pance, Epi Biologics
Bispecific Antibodies for Targeted Degradation of Extracellular Proteins
Bispecific Antibodies for Targeted Degradation of Extracellular Proteins
Wendy Ritacco, AbbVie Bioresearch Center
A Targeted Conditional PSCA-CTLA4 DVD-Ig for Immuno-Oncology: POC in Syngeneic Tumor and Metastasis Models
A Targeted Conditional PSCA-CTLA4 DVD-Ig for Immuno-Oncology: POC in Syngeneic Tumor and Metastasis Models
Edward van der Horst, Sensei Biotherapeutics
Short Talk: SNS-101, A Conditionally Active Anti-VISTA Antibody, Potentiates Anti-tumor Effects of PD-1 Blockade and Displays Favorable Pharmacokinetic and Cytokine Release Characteristics
Short Talk: SNS-101, A Conditionally Active Anti-VISTA Antibody, Potentiates Anti-tumor Effects of PD-1 Blockade and Displays Favorable Pharmacokinetic and Cytokine Release Characteristics
Coffee Break
9:30–9:50 AM
Riverview Lounge
On Own for Lunch
11:15–5:00 PM
Poster Setup
11:15–1:00 PM
Alberta/New Brunswick
Poster Viewing
1:00–10:00 PM
Alberta/New Brunswick
Workshop 1: New Ab Therapeutics and Engineering Platforms
2:30–4:30 PM
Cascade Ballroom
Yanay Ofran, Biolojic
A Computationally Designed Selective Agonist/Antagonist anti-IL-2 Antibody Redirects Endogenous Human IL-2 to Enhance Teff Function, while Antagonizing Tregs
A Computationally Designed Selective Agonist/Antagonist anti-IL-2 Antibody Redirects Endogenous Human IL-2 to Enhance Teff Function, while Antagonizing Tregs
Maxwell A Stefan, Twist Biosciences
Discovery of Novel Complement component 5a Receptor 1 Antagonistic Antibodies Using a Target-Specific Generated Phage Library
Discovery of Novel Complement component 5a Receptor 1 Antagonistic Antibodies Using a Target-Specific Generated Phage Library
Nazanin Rohani Larijani, National Research Council
CAIX VHH-based Therapies for Specific Targeting of Hypoxic Solid Tumor Areas
CAIX VHH-based Therapies for Specific Targeting of Hypoxic Solid Tumor Areas
Frank J. Beurskens, Genmab
Engineered Mutually-dependent IgG Antibody Combinations that Selectively Act on Cells Co-expressing Two Antigens
Engineered Mutually-dependent IgG Antibody Combinations that Selectively Act on Cells Co-expressing Two Antigens
Adam Zwolak, Janssen R&D
Mucosal Targeting of Antibodies: Hitchhiking on the Polymeric Ig Receptor
Mucosal Targeting of Antibodies: Hitchhiking on the Polymeric Ig Receptor
* Christoph Rader, UF Scripps Biomedical Research, University of Florida
Concerted Antibody and Antigen Discovery by Differential Whole-cell Phage Display Selections and Multiomic Target Deconvolution
Concerted Antibody and Antigen Discovery by Differential Whole-cell Phage Display Selections and Multiomic Target Deconvolution
Malin Jönsson, KTH Royal Institute of Technology
CaRA - Calcium-Regulated Affinity Domains with Novel Target Specificities for Enhanced Therapeutic Potential
CaRA - Calcium-Regulated Affinity Domains with Novel Target Specificities for Enhanced Therapeutic Potential
Lorenzo Maso, NYULMC
Creating MHC-restricted Neoantigens with Covalent Inhibitors that can be Targeted by Immune Therapy
Creating MHC-restricted Neoantigens with Covalent Inhibitors that can be Targeted by Immune Therapy
Coffee Available
4:30–5:00 PM
Riverview Lounge
Antibody Modality
5:00–7:00 PM
Cascade Ballroom
Shelley Ackerman, Bolt Biotherapeutics
Remote Presentation: Development of Immune Stimulating Antibody Conjugates to Promote Durable Antitumor Immunity
Remote Presentation: Development of Immune Stimulating Antibody Conjugates to Promote Durable Antitumor Immunity
* John R. Desjarlais, Xencor, Inc.
A Variety of Antibody-based Modalities for T Cell Signals 1, 2, and 3
A Variety of Antibody-based Modalities for T Cell Signals 1, 2, and 3
Sai T. Reddy, ETH Zurich
Engineering Synthetic T Cell Receptors for Enhanced Potency and Specificity
Engineering Synthetic T Cell Receptors for Enhanced Potency and Specificity
Francisco Leon, Provention Bio, Inc
Bi-Specific B Cell Targeting Diabody DART for Gene Therapy, SLE and Other Autoimmune Disorders
Bi-Specific B Cell Targeting Diabody DART for Gene Therapy, SLE and Other Autoimmune Disorders
Social Hour with Lite Bites
7:00–8:00 PM
Alberta/New Brunswick
Poster Session 1
7:30–10:00 PM
Alberta/New Brunswick
Tuesday, February 21, 2023
Breakfast
7:00–8:00 AM
Alberta/New Brunswick
New Approaches Toward Target Identification
8:00–11:00 AM
Cascade Ballroom
* Bernd Wollscheid, ETH Zürich
Leveraging Surfaceome Nanoscale Organization for Theranostics
Leveraging Surfaceome Nanoscale Organization for Theranostics
James A. Wells, University of California, San Francisco
Cell Surface Protolysis for Neo-Epitopes
Cell Surface Protolysis for Neo-Epitopes
Niyi Fadeyi, InduPro
A Photocatalytic Toolbox for Cataloging Inherent Protein Proximity at the Membrane Surface
A Photocatalytic Toolbox for Cataloging Inherent Protein Proximity at the Membrane Surface
Erica Ollmann Saphire, La Jolla Institute for Immunology
Structural Biology of Viruses Toward Therapeutic Development
Structural Biology of Viruses Toward Therapeutic Development
Garrett Rappazzo, Adimab LLC
Short Talk: Rapid Engineering of Soluble T Cell Receptors for Enhanced Affinity via a High-throughput Yeast-based Platform
Short Talk: Rapid Engineering of Soluble T Cell Receptors for Enhanced Affinity via a High-throughput Yeast-based Platform
Coffee Break
9:00–9:20 AM
Riverview Lounge
On Own for Lunch
11:00–5:00 PM
Poster Setup
11:00–1:00 PM
Alberta/New Brunswick
Poster Viewing
1:00–10:00 PM
Alberta/New Brunswick
Workshop 2: Emerging Approaches to Expand Biologic Therapies
2:30–4:00 PM
Cascade Ballroom
* Andrea Imle, BioNTech SE
Session Chair
Session Chair
Benjamin Bell, Merck & Co., Inc.
Enzyme Engineering of Human Hyaluronidase-1 for Subcutaneous Delivery of Biologics
Enzyme Engineering of Human Hyaluronidase-1 for Subcutaneous Delivery of Biologics
Andrea Imle, BioNTech SE
HexaBody-CD27 Enhances Proliferation, Cytokine Secretion and Cytotoxic Activity of Activated T cells without Requirement for Fc Gamma Receptor-mediated Crosslinking
HexaBody-CD27 Enhances Proliferation, Cytokine Secretion and Cytotoxic Activity of Activated T cells without Requirement for Fc Gamma Receptor-mediated Crosslinking
Jonathan Back, GlycoEra
Glycoengineered Lysosomal-Targeting Constructs (G-LyTAC) engaging ASGPR: A Novel Class of Targeted Extracellular Proteins Degraders
Glycoengineered Lysosomal-Targeting Constructs (G-LyTAC) engaging ASGPR: A Novel Class of Targeted Extracellular Proteins Degraders
Noel T. Pauli, Adimab LLC
Efficient Antibody Discovery against Membrane-obligate Drug Targets Utilizing a Yeast-based, Single B cell Cloning Platform
Efficient Antibody Discovery against Membrane-obligate Drug Targets Utilizing a Yeast-based, Single B cell Cloning Platform
Shaheen Farhadi, Merck & Co., Inc.
Targeting Interleukin-12 and -23 Private Receptors with Agonist Antibodies
Targeting Interleukin-12 and -23 Private Receptors with Agonist Antibodies
Coffee Available
4:30–5:00 PM
Riverview Lounge
Emerging Costimulatory Therapies in Oncology (Joint)
5:00–7:00 PM
Cascade Ballroom
* Pablo Umaña, Roche Innovation Center Zürich
Off-the-Shelf Enhanced T Cell Redirection via Tumor-Targeted Costimulatory Agonist and Engager Combinations
Off-the-Shelf Enhanced T Cell Redirection via Tumor-Targeted Costimulatory Agonist and Engager Combinations
Janelle Christine Waite, Regeneron
Tumor-Targeted Costimulation via Bispecific CD28 Antibodies
Tumor-Targeted Costimulation via Bispecific CD28 Antibodies
* Pamela M. Holland, InduPro
Conditional Targeting of CD28 in the Tumor Micorenvironment
Conditional Targeting of CD28 in the Tumor Micorenvironment
Sara Majocchi, Novimmune SA
Tumor and Immune Checkpoint-Dependent CD28 Agonism Using Bispecific Antibodies
Tumor and Immune Checkpoint-Dependent CD28 Agonism Using Bispecific Antibodies
Social Hour with Lite Bites
7:00–8:00 PM
Alberta/New Brunswick
Poster Session 2
7:30–10:00 PM
Alberta/New Brunswick
Wednesday, February 22, 2023
Breakfast
7:00–8:00 AM
Alberta/New Brunswick
Discovery Platforms
8:00–11:00 AM
Cascade Ballroom
* Jamie Spangler, Johns Hopkins University
A Suspension-based Cell-cell Interaction Platform for Membrane Protein-targeted Antibody Discovery
A Suspension-based Cell-cell Interaction Platform for Membrane Protein-targeted Antibody Discovery
Shohei Koide, New York University Langone Health
Targeting Intracellular Proteins with Biologics
Targeting Intracellular Proteins with Biologics
Mart Ustav Jr., Icosagen Therapeutics
Functional Antibodies Against Multi Span Transmembrane Proteins - Revisiting the Warburg Effect in Cancer Cells
Functional Antibodies Against Multi Span Transmembrane Proteins - Revisiting the Warburg Effect in Cancer Cells
Nora Karnowski, Apis Assay Technologies Ltd
Short Talk: Targeting Highly Homologous Pathogens With Supremely Specific Clickmers
Short Talk: Targeting Highly Homologous Pathogens With Supremely Specific Clickmers
Bhuvaneshwari Shunmuganathan, National University of Singapore
Short Talk: The Application of Advanced Antibody Engineering Methodologies for Development of Prognostic and Diagnostic Assays for COVID-19
Short Talk: The Application of Advanced Antibody Engineering Methodologies for Development of Prognostic and Diagnostic Assays for COVID-19
Coffee Break
9:00–9:20 AM
Riverview Lounge
On Own for Lunch
11:00–5:00 PM
Career Roundtable
3:00–4:30 PM
Alhambra
Markus G G. Manz, University Hospital Zürich
Department Chair, Prof. of Hematology
Department Chair, Prof. of Hematology
Francisco Leon, Provention Bio, Inc
Chief Scientific Officer, Co-Founder
Chief Scientific Officer, Co-Founder
Jamie Spangler, Johns Hopkins University
Assistant Professor
Assistant Professor
Coffee Available
4:30–5:00 PM
Riverview Lounge
Emerging Antibody Therapeutics in Infectious Disease
5:00–6:45 PM
Cascade Ballroom
* James A. Wells, University of California, San Francisco
Session Chair
Session Chair
Christopher O. Barnes, Stanford University
Structural Characterization of Antibody Responses to SARS-CoV-2
Structural Characterization of Antibody Responses to SARS-CoV-2
Ting Y Wong, WRAIR
Short Talk: Murine Monoclonal Antibodies against Secreted Staphylococcus Aureus Prothrombin-activating Virulence Factors Induce Macrophage Opsonophagocytosis
Short Talk: Murine Monoclonal Antibodies against Secreted Staphylococcus Aureus Prothrombin-activating Virulence Factors Induce Macrophage Opsonophagocytosis
Elizabeth Parzych, The Wistar Institute
Short Talk: Development of DNA-encoded, Functionally- enhanced Antibody Therapeutics against SARS-CoV-2
Short Talk: Development of DNA-encoded, Functionally- enhanced Antibody Therapeutics against SARS-CoV-2
Jason Kang, West Virginia University
Short Talk: Monoclonal Antibodies to Lipopolysaccharide Protect against Pseudomonas Aeruginosa Infection
Short Talk: Monoclonal Antibodies to Lipopolysaccharide Protect against Pseudomonas Aeruginosa Infection
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Cascade Ballroom
Social Hour with Lite Bites
7:00–8:00 PM
Alberta/New Brunswick
Cash Bar
8:00–11:00 PM
Alberta/New Brunswick
Thursday, February 23, 2023
Departure
8:00–8:00 AM
Subscribe for Updates